Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Moleculin Biotech CS (MBRX)

Moleculin Biotech CS (MBRX)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Moleculin Announces Positive Independent Report of No Cardiotoxicity in Annamycin Phase 1 To Date

Moleculin Biotech, Inc., (Nasdaq: MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting highly resistant tumors, today announced...

MBRX : 0.69 (-9.45%)
WPD Pharmaceuticals' STAT3 Inhibitor Received FDA Approval of IND Status in Pediatric Brain Cancer Trial

WPD Pharmaceuticals Inc. (CSE: WBIO)(FSE: 8SV1) (the "Company" or "WPD"), a clinical stage pharmaceutical company is pleased to provide an update on its WP1066 drug in the treatment of pediatric brain...

WBIO.CN : 1.160 (-7.20%)
MBRX : 0.69 (-9.45%)
WPD Pharmaceuticals' WP1220 Drug Demonstrates Median Reduction of 56% in Skin Cancer Lesions in Clinical Trials

WPD Pharmaceuticals Inc. (CSE: WBIO)(FSE: 8SV1) (the "Company" or "WPD"), a clinical stage pharmaceutical company, in collaboration with license partner, Moleculin Biotech, Inc. ("Moleculin")(Nasdaq: MBRX)...

WBIO.CN : 1.160 (-7.20%)
MBRX : 0.69 (-9.45%)
Moleculin Presents Clinical Trial Data Demonstrating a Median Reduction of 56% in Skin Cancer Lesions

Moleculin Biotech, Inc., (Nasdaq: MBRX) (Moleculin or the Company), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting highly resistant tumors, announced the final...

MBRX : 0.69 (-9.45%)
Moleculin Announces $6.0 Million Registered Direct Offering

Moleculin Biotech, Inc., (NASDAQ: MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting highly resistant tumors, today announced...

MBRX : 0.69 (-9.45%)
R&D Leading to Supported Progress for Treating Acute Myeloid Leukemia (AML)

Acute Myeloid Leukemia (AML) research has seen great progress with more researchers are now studying the causes, diagnosis, and treatment of Acute myeloid leukemia (AML) at many medical centers, university...

MBRX : 0.69 (-9.45%)
LJPC : 7.06 (-2.22%)
INSM : 26.34 (-11.76%)
TEVA : 13.24 (+4.25%)
PBYI : 11.31 (-9.88%)
Moleculin to Seek Accelerated FDA Approval and Plans for Pivotal Phase 2 AML Trial

Moleculin Biotech, Inc., (Nasdaq: MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting highly resistant tumors, today announced...

MBRX : 0.69 (-9.45%)
WPD Pharmaceuticals' Annamycin Drug Received FDA Approval of Fast Track Designation

WPD Pharmaceuticals Inc. (CSE: WBIO) (FSE: 8SV1) (the "Company" or "WPD"), a clinical stage pharmaceutical company, is pleased to provide an update on its Annamycin Drug. Through its development partner,...

WBIO.CN : 1.160 (-7.20%)
MBRX : 0.69 (-9.45%)
Moleculin Announces Successful Completion of US Phase 1 AML Trial of Annamycin

Moleculin Biotech, Inc., (Nasdaq: MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting highly resistant tumors, today announced...

MBRX : 0.69 (-9.45%)
WPD Pharmaceuticals Completed the Acquisition of Two Pancreatic Cancer Drug Candidates

WPD Pharmaceuticals Inc. (CSE: WBIO)(FSE: 8SV1) (the "Company" or "WPD"), a clinical stage pharmaceutical company, provides this update on the completed acquisition of exclusive sublicenses for two drug...

WBIO.CN : 1.160 (-7.20%)
MBRX : 0.69 (-9.45%)
Moleculin Announces New Data Shows Reversal of Tumor Activity in Animal Models

Moleculin Biotech, Inc., (Nasdaq: MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting highly resistant tumors, today announced...

MBRX : 0.69 (-9.45%)
Biotechs Move Forward Developing Latest Targeted Therapies for Acute Myeloid Leukemia

So it is not surprising that there is a lot of money and research resources being devoted to find new therapies for Acute Myeloid Leukemia (AML), many of which are in the targeted drugs arena. AML is the...

MBRX : 0.69 (-9.45%)
BOLD : 59.97 (-0.02%)
OTLK : 0.82 (-8.32%)
AXSM : 84.76 (-4.24%)
QURE : 54.52 (-6.60%)
Moleculin Announces Additional Positive Interim Results from Phase 1/2 Clinical Studies of Annamycin in Acute Myeloid Leukemia

Moleculin Biotech, Inc., (Nasdaq: MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting highly resistant tumors, today announced...

MBRX : 0.69 (-9.45%)
Moleculin Announces Positive Trial Data with 100% Safe Delivery of p-STAT3 Inhibitor and Efficacy in Majority of Patients

Moleculin Biotech, Inc., (Nasdaq: MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting highly resistant tumors, announced it...

MBRX : 0.69 (-9.45%)
Today's New Way to Fight Cancer Focusing on Metabolic Therapies

For decades researchers have been trying to find newer and more effective ways to fight cancer cells. Today much research is focused on attacking the cancerous cells growth. The reasoning is that denying...

MBRX : 0.69 (-9.45%)
AMRN : 17.50 (-0.46%)
KDMN : 4.30 (-6.32%)
PFE : 33.93 (-2.13%)
ACST : 0.50 (-6.25%)
ACST.VN : 0.660 (-4.35%)
Moleculin Announces Beginning of Preclinical Development of New Approach to Pancreatic Cancer

Moleculin Biotech, Inc., (Nasdaq: MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting highly resistant tumors, announced it...

MBRX : 0.69 (-9.45%)
Biotechs Seek Advancements in the Immuno-Oncology Field for Childhood Brain Tumors

Doctors are working to learn more about brain tumors, ways to prevent them, how to best treat them, and how to provide the best care to people diagnosed with a brain tumor. According to recent articles...

MBRX : 0.69 (-9.45%)
ABBV : 89.18 (-4.25%)
NKTR : 22.15 (-0.94%)
INMD : 33.64 (-6.40%)
AGEN : 2.97 (-11.61%)
Moleculin Announces FDA Approval of IND for its STAT3 Inhibitor in Emory University Clinical Trial

Moleculin Biotech, Inc., (Nasdaq: MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting highly resistant tumors, announced that...

MBRX : 0.69 (-9.45%)
Moleculin Biotech, Inc. Reports Financial Results for the Third Quarter Ended September 30, 2019

Moleculin Biotech, Inc., (NASDAQ: MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting highly resistant tumors, today announced...

MBRX : 0.69 (-9.45%)
Clinical Trials in Gene Sequencing Reveal Novel Mutations Aiding in New Treatments for Acute Myeloid Leukemia

Palm Beach, FL -October 29, 2019 - Acute myeloid leukemia (AML), is the most common of the four major types of leukemia. Without treatment, AML is often deadly within a few months. Many of the symptoms...

MBRX : 0.69 (-9.45%)
DCPH : 53.85 (+0.04%)
RIGL : 2.15 (-2.27%)
NKTR : 22.15 (-0.94%)
BDSI : 5.11 (-2.67%)

Van Meerten Stock Picks

My 5 Favorite Mid Caps
Summary 100% technical buy signals with current momentum.
CRUS -1.74 , SEDG -2.63 , THC -3.44 , TER -2.25 , LITE -2.20
Jim Van Meerten uses Barchart's tools to offer daily stock picks and recommendations. His portfolios have been honored by Marketocracy and Morningstar.

InsideFutures Commentary

InsideFutures is a twice weekly newsletter that features a selection of the latest and best commodities commentary appearing on Barchart.com. Delivered every Wednesday and Friday morning to your inbox.

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar